Talimogene laherparepvec and Xpovio (80 MG Twice Weekly)
Determining the interaction of Talimogene laherparepvec and Xpovio (80 MG Twice Weekly) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.CONTRAINDICATED: Talimogene laherparepvec is a live, attenuated herpes simplex virus. Administration during immunosuppressant or intense antineoplastic therapy may be associated with a risk of potentially life-threatening disseminated herpetic infection due to enhanced virus replication in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. MANAGEMENT: Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient's immune system has sufficiently recovered. References "Product Information. Imlygic (talimogene laherparepvec)." Amgen USA, Thousand Oaks, CA.
Professional:CONTRAINDICATED: Talimogene laherparepvec is a live, attenuated herpes simplex virus. Administration during immunosuppressant or intense antineoplastic therapy may be associated with a risk of potentially life-threatening disseminated herpetic infection due to enhanced virus replication in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.
MANAGEMENT: Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient's immune system has sufficiently recovered.
- "Product Information. Imlygic (talimogene laherparepvec)." Amgen USA, Thousand Oaks, CA.
Generic Name: talimogene laherparepvec
Brand name: Imlygic
Synonyms: Talimogene Laherparepvec
Generic Name: selinexor
Brand name: Xpovio
Synonyms: Xpovio
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Talimogene laherparepvec-Xryliderm
- Talimogene laherparepvec-Xrylix
- Talimogene laherparepvec-Xtampza ER
- Talimogene laherparepvec-Xtandi
- Talimogene laherparepvec-Xtramins
- Talimogene laherparepvec-Xtrelus
- Xpovio (80 MG Twice Weekly)-Talimogene laherparepvec Injection
- Xpovio (80 MG Twice Weekly)-Taliva
- Xpovio (80 MG Twice Weekly)-Taltz
- Xpovio (80 MG Twice Weekly)-Taltz (Ixekizumab Auto-Injectors)
- Xpovio (80 MG Twice Weekly)-Taltz (Ixekizumab Prefilled Syringes)
- Xpovio (80 MG Twice Weekly)-Talwin